Kirby McInerney LLP is investigating Celcuity Inc. for possible securities fraud following the company's announcement of a delayed commercial launch for its FDA-approved breast cancer therapy, Revtorpyk. The launch delay to late Q3 2026 was later than analysts expected, causing Celcuity's stock to drop 17.6%. The law firm is examining whether Celcuity or its senior management violated federal securities laws. No lawsuit has been filed yet, and the investigation is ongoing.
Charles Schwab announced record second-quarter results with $7.07 billion in revenue and $1.62 adjusted EPS, a 42% increase year-over-year. The company added 1.4 million new brokerage accounts and $120 billion in net new assets, signaling strong clie...
D.R. Horton reported strong quarterly earnings with an EPS of $3.20 and revenue of $9.23 billion, both exceeding analyst expectations. The results were driven by a 4% increase in home-closing volumes, totaling nearly 24,000 homes, along with contribu...
The U.S. Small Business Administration (SBA) announced a $6 million grant competition to fund the Women’s Business Center (WBC) Modernization Initiative. This initiative aims to expand statewide support networks for women entrepreneurs in eight state...
Copart's stock is under pressure following a Barclays analyst downgrade to a $26 price target and significant insider selling by a company director. The company faces a securities fraud investigation after CEO Jeff Liaw's resignation, which caused an...
Charles Schwab reported strong Q2 2026 results with earnings per share of $1.62, exceeding estimates and marking a 42% increase year-over-year. The company achieved record quarterly revenue of $7.07 billion, driven by increased trading activity and h...
